301 related articles for article (PubMed ID: 26626718)
61. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium.
Allen GP; Bierman BC
Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921
[TBL] [Abstract][Full Text] [Related]
62. Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
Shimizu T; Harada K; Kataoka Y
Acta Vet Scand; 2013 May; 55(1):37. PubMed ID: 23634902
[TBL] [Abstract][Full Text] [Related]
63. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Allen GP; Hankins CD
J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
[TBL] [Abstract][Full Text] [Related]
64. In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.
Zhang B; Gu X; Li Y; Li X; Gu M; Zhang N; Shen X; Ding H
BMC Vet Res; 2014 Dec; 10():297. PubMed ID: 25511985
[TBL] [Abstract][Full Text] [Related]
65. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.
van Zanten AR; Polderman KH; van Geijlswijk IM; van der Meer GY; Schouten MA; Girbes AR
J Crit Care; 2008 Sep; 23(3):422-30. PubMed ID: 18725050
[TBL] [Abstract][Full Text] [Related]
66. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Sirvent E; Ruiz M; Rodríguez JC; Royo G
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
[TBL] [Abstract][Full Text] [Related]
67. Mutant-prevention concentration and mechanism of resistance in clinical isolates and enrofloxacin/marbofloxacin-selected mutants of Escherichia coli of canine origin.
Gebru E; Choi MJ; Lee SJ; Damte D; Park SC
J Med Microbiol; 2011 Oct; 60(Pt 10):1512-1522. PubMed ID: 21596912
[TBL] [Abstract][Full Text] [Related]
68. The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration.
Blondeau JM; Hansen G; Metzler K; Hedlin P
J Chemother; 2004 Jun; 16 Suppl 3():1-19. PubMed ID: 15334827
[TBL] [Abstract][Full Text] [Related]
69. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica.
Randall LP; Cooles SW; Piddock LJ; Woodward MJ
J Antimicrob Chemother; 2004 Sep; 54(3):688-91. PubMed ID: 15243029
[TBL] [Abstract][Full Text] [Related]
70. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Int J Antimicrob Agents; 2004 Aug; 24(2):150-60. PubMed ID: 15288314
[TBL] [Abstract][Full Text] [Related]
71. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.
MacGowan AP; Wootton M; Holt HA
J Antimicrob Chemother; 1999 Mar; 43(3):345-9. PubMed ID: 10223589
[TBL] [Abstract][Full Text] [Related]
72. Susceptibility and PK/PD relationships of
Serrano-Rodríguez JM; Cárceles-García C; Cárceles-Rodríguez CM; Gabarda ML; Serrano-Caballero JM; Fernández-Varón E
Vet Rec; 2017 Apr; 180(15):376. PubMed ID: 28213532
[TBL] [Abstract][Full Text] [Related]
73. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
[TBL] [Abstract][Full Text] [Related]
74. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.
Khan DD; Lagerbäck P; Cao S; Lustig U; Nielsen EI; Cars O; Hughes D; Andersson DI; Friberg LE
J Antimicrob Chemother; 2015 Nov; 70(11):3051-60. PubMed ID: 26349518
[TBL] [Abstract][Full Text] [Related]
75. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
76. Using In Vitro Dynamic Models To Evaluate Fluoroquinolone Activity against Emergence of Resistant Salmonella enterica Serovar Typhimurium.
Lee SJ; Awji EG; Park NH; Park SC
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895011
[TBL] [Abstract][Full Text] [Related]
77. Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Srivastava P; Sivashanmugam K
Infect Genet Evol; 2021 Aug; 92():104824. PubMed ID: 33774177
[TBL] [Abstract][Full Text] [Related]
78. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.
Firsov AA; Vostrov SN; Lubenko IY; Drlica K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2003 May; 47(5):1604-13. PubMed ID: 12709329
[TBL] [Abstract][Full Text] [Related]
79. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.
Firsov AA; Alferova IV; Smirnova MV; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2005 May; 25(5):409-13. PubMed ID: 15848296
[TBL] [Abstract][Full Text] [Related]
80.
Allen GP; Harris KA
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483960
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
